NO941799D0 - Nye substituerte salicylsyrer - Google Patents

Nye substituerte salicylsyrer

Info

Publication number
NO941799D0
NO941799D0 NO941799A NO941799A NO941799D0 NO 941799 D0 NO941799 D0 NO 941799D0 NO 941799 A NO941799 A NO 941799A NO 941799 A NO941799 A NO 941799A NO 941799 D0 NO941799 D0 NO 941799D0
Authority
NO
Norway
Prior art keywords
compound
salicylic acids
new substituted
substituted salicylic
het
Prior art date
Application number
NO941799A
Other languages
English (en)
Other versions
NO300805B1 (no
NO941799L (no
Inventor
Karl Hubert Agback
Leif Ahrgren
Thomas Berglindh
Martin Haraldsson
Lars-Inge Olsson
Goran Smedegaard
Original Assignee
Pharmacia Ab
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab, Kabi Pharmacia Ab filed Critical Pharmacia Ab
Publication of NO941799D0 publication Critical patent/NO941799D0/no
Publication of NO941799L publication Critical patent/NO941799L/no
Publication of NO300805B1 publication Critical patent/NO300805B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/76Nitrogen atoms to which a second hetero atom is attached
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D261/00Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14Nitrogen atoms
    • C07D261/16Benzene-sulfonamido isoxazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
NO941799A 1991-11-18 1994-05-13 Nye substituerte salicylsyrer NO300805B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9103397A SE9103397D0 (sv) 1991-11-18 1991-11-18 Nya substituerade salicylsyror
PCT/SE1992/000758 WO1993010094A1 (en) 1991-11-18 1992-11-04 Novel substituted salicyclic acids

Publications (3)

Publication Number Publication Date
NO941799D0 true NO941799D0 (no) 1994-05-13
NO941799L NO941799L (no) 1994-06-22
NO300805B1 NO300805B1 (no) 1997-07-28

Family

ID=20384352

Family Applications (1)

Application Number Title Priority Date Filing Date
NO941799A NO300805B1 (no) 1991-11-18 1994-05-13 Nye substituerte salicylsyrer

Country Status (29)

Country Link
US (3) US5302718A (no)
EP (1) EP0613468B1 (no)
JP (1) JP3259915B2 (no)
KR (1) KR100253748B1 (no)
AT (1) ATE194597T1 (no)
AU (1) AU668528B2 (no)
CA (1) CA2123697C (no)
DE (1) DE69231252T2 (no)
DK (1) DK0613468T3 (no)
EE (1) EE03026B1 (no)
ES (1) ES2149780T3 (no)
FI (1) FI106857B (no)
GR (1) GR3034585T3 (no)
HU (2) HU221476B (no)
IL (1) IL103665A (no)
LT (1) LT3182B (no)
LV (1) LV10246B (no)
MX (1) MX9206647A (no)
MY (1) MY130169A (no)
NO (1) NO300805B1 (no)
NZ (1) NZ244998A (no)
PT (1) PT101068B (no)
RU (1) RU2124501C1 (no)
SE (1) SE9103397D0 (no)
SK (1) SK282080B6 (no)
TW (1) TW304944B (no)
UA (1) UA42869C2 (no)
WO (1) WO1993010094A1 (no)
ZA (1) ZA928864B (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514696A (en) * 1992-05-06 1996-05-07 Bristol-Myers Squibb Co. Phenyl sulfonamide endothelin antagonists
GB9310095D0 (en) * 1993-05-17 1993-06-30 Zeneca Ltd Therapeutic compounds
US5965732A (en) * 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US5405842A (en) * 1994-01-28 1995-04-11 Silverman; Bernard A. Treatment of steroid dependent asthmatics
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5846990A (en) * 1995-07-24 1998-12-08 Bristol-Myers Squibb Co. Substituted biphenyl isoxazole sulfonamides
US6028052A (en) * 1995-09-18 2000-02-22 Ligand Pharmaceuticals Incorporated Treating NIDDM with RXR agonists
JPH09124620A (ja) 1995-10-11 1997-05-13 Bristol Myers Squibb Co 置換ビフェニルスルホンアミドエンドセリン拮抗剤
HUP0002351A3 (en) 1996-02-20 2001-10-29 Bristol Myers Squibb Co Methods for the preparation of biphenyl isoxazole sulfonamides, intermediates and process for preparing them
US5856507A (en) * 1997-01-21 1999-01-05 Bristol-Myers Squibb Co. Methods for the preparation of biphenyl isoxazole sulfonamides
US5939446A (en) * 1996-04-09 1999-08-17 Bristol-Myers Squibb Co. Heteroaryl substituted phenyl isoxazole sulfonamide endothelin antagonists
JP3814742B2 (ja) * 1996-10-18 2006-08-30 イハラケミカル工業株式会社 4−フルオロサリチル酸類
AU6187898A (en) * 1997-01-30 1998-08-25 Bristol-Myers Squibb Company Method for preventing or treating low renin hypertension by administering an endothelin antagonist
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GB9804648D0 (en) 1998-03-06 1998-04-29 Zeneca Ltd Chemical compounds
GB9805520D0 (en) * 1998-03-17 1998-05-13 Zeneca Ltd Chemical compounds
GB9811427D0 (en) 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
CA2334545A1 (en) 1998-06-12 1999-12-16 Ligand Pharmaceuticals Incorporated Treatment of anti-estrogen resistant breast cancer using rxr modulators
WO2000056685A1 (en) 1999-03-19 2000-09-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
ATE344237T1 (de) 1999-09-04 2006-11-15 Astrazeneca Ab Hydroxyacetamidobenzolsulfonamidderivate
HUP0202725A3 (en) 1999-09-04 2005-04-28 Astrazeneca Ab Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3-trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity, process for their preparation and pharmaceutical compositions containing them
US6878712B1 (en) 1999-09-04 2005-04-12 Astrazeneca Ab Amides as inhibitors for pyruvate dehydrogenase
CA2307278A1 (en) * 2000-04-28 2001-10-28 University Of British Columbia Use of n-heterocyclic substituted salicylic acids for inhibition of cellular uptake of cystine
EP1278521B1 (en) * 2000-04-28 2005-11-30 The University of British Columbia N-heterocyclic substituted salicylates for the treatment of cancer
US6639082B2 (en) 2000-10-17 2003-10-28 Bristol-Myers Squibb Company Methods for the preparation of biphenyl isoxazole sulfonamides
WO2005023771A1 (ja) * 2003-09-05 2005-03-17 Ono Pharmaceutical Co., Ltd. ケモカインレセプターアンタゴニストおよびその医薬用途
JP2007514731A (ja) * 2003-12-19 2007-06-07 ファイザー インコーポレイテッド 糖尿病及び肥満症の治療のための11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ1型(11−β−hsd−1)の阻害剤としてのベンゼンスルホニルアミノ−ピリジン−2−イル誘導体及び関連化合物
EP1763353A1 (en) * 2004-06-29 2007-03-21 Warner-Lambert Company LLC COMBINATION THERAPIES UTILIZING BENZAMIDE INHIBITORS OF THE P2X<sb>7</sb> RECEPTOR
GB2421947A (en) * 2005-01-07 2006-07-12 Univ Southampton Sulphonamide compounds for use as inhibitors of NF-kB
WO2007098169A1 (en) * 2006-02-21 2007-08-30 Amgen Inc. Cinnoline derivatives as phosphodiesterase 10 inhibitors
US8314240B2 (en) * 2008-06-23 2012-11-20 Astellas Pharma Inc. Sulfonamide compounds or salts thereof
WO2012116170A1 (en) * 2011-02-23 2012-08-30 Ming-Ming Zhou Inhibitors of bromodomains as modulators of gene expression
BR112017024618B1 (pt) 2015-05-20 2023-03-14 Amgen Inc Compostos agonistas de triazol do receptor apj, composições e usos relacionados
CN108602775B (zh) 2016-01-14 2022-04-29 贝思以色列女会吏医学中心公司 肥大细胞调节剂及其用途
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
WO2018093577A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
WO2018093580A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
US10906890B2 (en) 2016-11-16 2021-02-02 Amgen Inc. Triazole phenyl compounds as agonists of the APJ receptor
EP3541802A1 (en) 2016-11-16 2019-09-25 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
MA50509A (fr) 2017-11-03 2021-06-02 Amgen Inc Agonistes de triazole fusionnés du récepteur apj
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor
CN111056978B (zh) * 2019-12-13 2021-01-19 西安交通大学 一种磺酰胺类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2396145A (en) * 1940-12-14 1946-03-05 Pharmscia Ab Heterocyclic sulphonamido azo compounds
BE791889A (fr) * 1971-11-26 1973-05-24 Pharmacia Ab Nouveaux derives de la pyridine
US4663334A (en) * 1985-12-11 1987-05-05 Mcneilab, Inc. Heteroaromatic acetylenes useful as antihypertensive agents
US4897397A (en) * 1988-12-16 1990-01-30 Schering Corporation Aryl-alkynoic, alkenoic or alkanoic compounds and compositions useful as antiallergy and anti-inflammatory agents

Also Published As

Publication number Publication date
CA2123697C (en) 2003-12-09
EP0613468A1 (en) 1994-09-07
JPH07501330A (ja) 1995-02-09
DE69231252D1 (de) 2000-08-17
MX9206647A (es) 1993-05-01
US5556855A (en) 1996-09-17
HU9401391D0 (en) 1994-08-29
SE9103397D0 (sv) 1991-11-18
LTIP229A (en) 1994-09-25
KR100253748B1 (ko) 2000-05-01
LV10246B (en) 1995-04-20
DK0613468T3 (da) 2000-10-23
RU2124501C1 (ru) 1999-01-10
FI942289A0 (fi) 1994-05-17
IL103665A0 (en) 1993-04-04
HUT69723A (en) 1995-09-28
NZ244998A (en) 1995-09-26
PT101068A (pt) 1994-02-28
JP3259915B2 (ja) 2002-02-25
NO300805B1 (no) 1997-07-28
US5403930A (en) 1995-04-04
FI106857B (fi) 2001-04-30
DE69231252T2 (de) 2001-03-01
AU668528B2 (en) 1996-05-09
UA42869C2 (uk) 2001-11-15
ATE194597T1 (de) 2000-07-15
EP0613468B1 (en) 2000-07-12
HU211163A9 (en) 1995-10-30
SK54794A3 (en) 1995-02-08
TW304944B (no) 1997-05-11
MY130169A (en) 2007-06-29
LT3182B (en) 1995-03-27
HU221476B (en) 2002-10-28
NO941799L (no) 1994-06-22
ZA928864B (en) 1993-05-13
CA2123697A1 (en) 1993-05-27
IL103665A (en) 1997-08-14
AU2958992A (en) 1993-06-15
GR3034585T3 (en) 2001-01-31
EE03026B1 (et) 1997-08-15
LV10246A (lv) 1994-10-20
US5302718A (en) 1994-04-12
WO1993010094A1 (en) 1993-05-27
SK282080B6 (sk) 2001-10-08
ES2149780T3 (es) 2000-11-16
PT101068B (pt) 1999-08-31
FI942289A (fi) 1994-05-17

Similar Documents

Publication Publication Date Title
NO941799D0 (no) Nye substituerte salicylsyrer
RU94028109A (ru) Новые замещенные салициловые кислоты, способ их получения
DK0638071T3 (da) Heterocykliske carboxylsyrederivater, der bindes til retenoidreceptorer (RAR)
PE58699A1 (es) Derivados de acido arilsulfonil hidroxamico
FI940414A (fi) Kinoliini- tai kinatsoliinijohdannaiset, niiden valmistus ja käyttö
PT100332A (pt) Agentes para o tratamento de doencas cardiovasculares derivados de piridina e imidazole
TH13794EX (th) ซับสทิทิวเทดซาลิไซลิคแอซิดชนิดใหม่
NO990483L (no) Nye polycykliske ftalazinderivater og deres anvendelse
ATE361307T1 (de) Neue arzneimittel